Lantheus Q3 net income falls 19% to $22.4 million

By Public Technologies
  • Lantheus’ third-quarter 2026 GAAP diluted earnings fell 20% to $0.33 per share, while revenue rose to $389.9 million.
  • Neuraceq revenue more than doubled to $45.6 million, while PYLARIFY revenue declined to $238.9 million.
  • The FDA granted approval for Alzheimer’s imaging agent TAUKLARIFY and final approval for neuroendocrine tumor treatment BRAVNETSA.
  • The pending Curium merger offers $102.50 per share in cash and contingent value rights worth up to $12 per share.
  • Full-year 2026 financial guidance was suspended in connection with the pending transaction.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantheus Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050700PRIMZONEFULLFEED9870782) on November 05, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk